Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sapitinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ERBB2 known ✓ | P04626 | 14/20 | 1.00 |
| ▸ | EGFR known ✓ | P00533 | 8/20 | 1.00 |
| ▸ | ERBB3 known ✓ | P21860 | 1/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | LYN | P07948 | 1/20 | 1.00 |
| ▸ | RET | P07949 | 1/20 | 1.00 |
| ▸ | EPHA1 | P21709 | 1/20 | 1.00 |
| ▸ | EPHA2 | P29317 | 1/20 | 1.00 |
| ▸ | EPHB2 | P29323 | 1/20 | 1.00 |
| ▸ | EPHA5 | P54756 | 1/20 | 1.00 |
| ▸ | EPHB4 | P54760 | 1/20 | 1.00 |
| ▸ | EPHA4 | P54764 | 1/20 | 1.00 |
| ▸ | ADK | P55263 | 1/20 | 1.00 |
| ▸ | PTK6 | Q13882 | 1/20 | 1.00 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sapitinib SCHEMBL30362790 | 1.00 | ERBB2 (1.00) | ERBB2EGFRGAKRIPK2LYN | |
| Sapitinib SCHEMBL29728247 | 1.00 | ERBB2 (1.00) | ERBB2EGFRGAKRIPK2LYN | |
| Sapitinib SCHEMBL201896 | 0.96 | ERBB2 (0.92) | ERBB2EGFRGAKRIPK2LYN | |
| Sapitinib SCHEMBL201895 | 0.96 | ERBB2 (0.92) | ERBB2EGFRGAKRIPK2LYN | |
| SCHEMBL4883773 | 0.93 | ERBB2 (1.00) | ERBB2EGFRGAKRIPK2LYN | |
| SCHEMBL29731571 | 0.92 | ERBB2 (0.87) | ERBB2EGFRGAKRIPK2LYN | |
| SCHEMBL4884254 | 0.92 | ERBB2 (0.87) | ERBB2EGFRGAKRIPK2LYN | |
| SCHEMBL29781246 | 0.92 | ERBB2 (1.00) | ERBB2EGFRGAKRIPK2LYN | |
| SCHEMBL3129641 | 0.92 | ERBB2 (1.00) | ERBB2EGFRGAKRIPK2LYN | |
| Hydrochloric Acid SCHEMBL4878789 | 0.92 | ERBB2 (0.86) | ERBB2EGFRGAKRIPK2LYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1601 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026103823-A1 | COMBINATION OF RAS INHIBITOR AND EGFR INHIBITOR AND USE THEREOF | 广州嘉越医药科技有限公司 | 2026-05-21 | — | — | WO | claimed |
| WO-2026107237-A1 | RAS AND EGFR INHIBITORS COMBINATION THERAPY | ERASCA, INC. (US) | 2026-05-21 | — | — | WO | claimed |
| EP-4133108-B1 | EPLIN AS A BIOMARKER FOR CANCER | THESTRA Oy (FI) | 2026-04-29 | — | — | EP | claimed |
| EP-4724150-A1 | A 1,5-DIHYDRO-4H-PYRROLO[3,2-C] PYRIDIN-4-ONE FOR USE IN THE TREATMENT OF CANCER | Antares Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| EP-4724151-A1 | A 1,5-DIHYDRO-4H-PYRROLO[3,2-C] PYRIDIN-4-ONE FOR USE IN THE TREATMENT OF CANCER | Antares Therapeutics, Inc. (US) | 2026-04-15 | — | — | EP | claimed |
| US-20260069596-A1 | USE OF PLK1 INHIBITOR AS MONOTHERAPY AND IN COMBINATION WITH CETUXIMAB IN TREATING RAS WILD-TYPE COLORECTAL CANCER | CARDIFF ONCOLOGY INC (US) | 2026-03-12 | — | — | US | claimed |
| US-12559800-B2 | KMT2A-MAML2 fusion molecules and uses thereof | FOUNDATION MEDICINE, INC. (US) | 2026-02-24 | — | — | US | claimed |
| US-20260049063-A1 | ALKYNYL QUINAZOLINE COMPOUNDS | BLACK DIAMOND THERAPEUTICS INC (US) | 2026-02-19 | — | — | US | claimed |
| US-12491186-B2 | EGFR inhibitors for treating keratodermas | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2025-12-09 | — | — | US | claimed |
| US-20250367201-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | VERASTEM INC (US) | 2025-12-04 | — | — | US | claimed |
| EP-2421827-A2 | PROCESS FOR THE PREPARATION OF 4-(3-CHLORO-2-FLUORO- ANILINO)-7-METHOXY-6- { [1-(N-METHYLCARBAMOYLMETHYL)- PIPERIDIN- 4-YL]OXY}QUINAZOLINE | AstraZeneca AB (SE) | 2012-02-29 | — | — | EP | claimed |
| EP-2303276-A1 | FUMARATE SALT OF 4- (3-CHLORO-2-FLUOROANILINO) -7-METHOXY-6- { [1- (N-METHYLCARBAMOYLMETHYL) PIPERIDIN- 4-YL]OXY}QUINAZOLINE | AstraZeneca AB (SE) | 2011-04-06 | — | — | EP | claimed |
| WO-2010122340-A2 | PROCESS 738 | ASTRAZENECA AB (SE) | 2010-10-28 | — | — | WO | claimed |
| WO-2010061208-A2 | THERAPEUTIC TREATMENT 555 | ASTRAZENECA AB (SE) | 2010-06-03 | — | — | WO | claimed |
| WO-2009138781-A1 | FUMARATE SALT OF 4- (3-CHLORO-2-FLUOROANILINO) -7-METHOXY-6- { [1- (N-METHYLCARBAMOYLMETHYL) PIPERIDIN- 4-YL] OXY}QUINAZOLINE | ASTRAZENECA AB (SE) | 2009-11-19 | — | — | WO | claimed |
| WO-2009138779-A1 | COMBINATION COMPRISING 4- (3-CHLORO-2-FLUOROANILINO) -7-METH0XY-6- { [1- (N-METHYLCARBAMOYLMETHYL) PIPERIDIN- 4-YL] OXYJQUINAZOLINE | ASTRAZENECA AB (SE) | 2009-11-19 | — | — | WO | claimed |
| US-20080096881-A1 | Quinazoline Derivatives | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | claimed |
| EP-1667992-B1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2007-01-24 | — | — | EP | claimed |
| EP-1667992-A1 | QUINAZOLINE DERIVATIVES | Astrazeneca AB (SE) | 2006-06-14 | — | — | EP | claimed |
| WO-2005028469-A1 | QUINAZOLINE DERIVATIVES | ASTRAZENECA AB (SE) | 2005-03-31 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12559800-B2 | KMT2A-MAML2 fusion molecules and uses thereof | DNER, EGFR, NOTCH2 | ERBB2 4/4885EGFR 2/4885ERBB3 23/4885 |
| US-20260069596-A1 | USE OF PLK1 INHIBITOR AS MONOTHERAPY AND IN COMBINATION WITH CETUXIMAB IN TREATING RAS WILD-TYPE COLORECTAL CANCER | PLK1, BRAF, KRAS | ERBB2 18/4885EGFR 6/4885ERBB3 17/4885 |
| US-12491186-B2 | EGFR inhibitors for treating keratodermas | MAP3K3, GRK3, TAS1R3 | ERBB2 181/4885EGFR 54/4885ERBB3 66/4885 |
| US-20250367201-A1 | COMBINATION THERAPY FOR TREATING ABNORMAL CELL GROWTH | KRAS, NRAS, HRAS | ERBB2 65/4885EGFR 24/4885ERBB3 128/4885 |
| US-20080096881-A1 | Quinazoline Derivatives | EGFR, ERBB2, ERBB3 | ERBB2 2/4885EGFR 1/4885ERBB3 3/4885 |
| US-20260049063-A1 | ALKYNYL QUINAZOLINE COMPOUNDS | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MCL1, BCL6 | ERBB2 428/4885EGFR 324/4885ERBB3 429/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.